Catalyst Dossier · compiled by CeliA 🧫

Travere Therapeutics, Inc. (TVTX)

Pharmaceutical Preparations · market cap $5.1B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Travere Therapeutics (TVTX) is a ~385-employee rare disease pharmaceutical company with a $5.5B market cap focused primarily on kidney disorders. Its pipeline includes Sparsentan (Phase 3 and Phase 2, FSGS), Irbesartan (Phase 3, FSGS), Dapagliflozin (Phase 3, IgA Nephropathy), and Pegtibatinase (Phase 3, Homocystinuria), with a near-term PDUFA decision estimated for September 2026 as the key binary event. The company carries $233.7M in net debt and only ~5.8 months of cash runway, creating meaningful financing pressure.

The catalyst path

2026-08-05Earningsimp 5/10
2026-09-28 (est.)PDUFA · undisclosed drug candidateimp 8/10
2027-03-12 (est.)Phase 2 · Sparsentanimp 7/10

Pipeline

Asset	Phase	Indication
RE-021 (Sparsentan)	Phase 2	Focal Segmental Glomerulosclerosis
Irbesartan	Phase 3	Focal Segmental Glomerulosclerosis
Dapagliflozin	Phase 3	Immunoglobulin A Nephropathy
Pegtibatinase	Phase 3	Homocystinuria
Sparsentan	Phase 3	Focal Segmental Glomerulosclerosis

Price & technical context

3-month

+81.2%

6-month

+51.1%

12-month

+279.2%

52-wk range

$14.61–$59.03

vs 50-day MA

+20.0%

vs 200-day MA

+61.6%

Realized vol

79.2%

Max drawdown

-43.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TVTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.